Aeschlimann C et al., 1996-12: Laboratory study showing methylene blue inhibits (mono)amine oxidase in vitro and in rat liver perfusions, blocking formation of the ifosfamide metabolite chloroacetaldehyde without inhibiting ifosfamide activation. It supplies the mechanistic rationale for methylene blue in ifosfamide encephalopathy.
The results provide an explanation for the preventive action of methylene blue in ifosfamide neurotoxicity, because the generation of chloroacetaldehyde (a potential neurotoxin of ifosfamide metabolism) is prevented in liver mitochondria and extrahepatic tissues.
Aeschlimann C et al., 1996-12: Laboratory study showing methylene blue inhibits (mono)amine oxidase in vitro and in rat liver perfusions, blocking formation of the ifosfamide metabolite chloroacetaldehyde without inhibiting ifosfamide activation. It supplies the mechanistic rationale for methylene blue in ifosfamide encephalopathy. Study type: in vitro enzyme assays plus rat liver perfusion (animal tissue). N: not applicable. Country: Switzerland (University of Bern). Dose: per full text (methylene blue micromolar range). Comparator: preparations without methylene blue. Funder/conflicts: not stated in record. Laboratory mechanism only, no patients; the clinical claim rests on MTM-22 and the review MTM-23. Also filed as MTJ-21 (claims C4). Study type: lab.
